Experienced in Fibroadenoma

Jinsong R. Lu

No.160 Pujian Road, 
Shanghai, CN 
Experienced in Fibroadenoma
No.160 Pujian Road, 
Shanghai, CN 
OverviewLocationsClinical Research

Overview

Jinsong Lu practices in Shanghai, China. Lu is rated as an Experienced expert by MediFind in the treatment of Fibroadenoma. Their top areas of expertise are Triple-Negative Breast Cancer, Breast Cancer, Cerebral Hypoxia, and Agranulocytosis.

Their clinical research consists of co-authoring 86 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Fibroadenoma.

Locations

No.160 Pujian Road, Shanghai, 200127, China
Other Locations
No. 1630 Dongfang Road, Dongfang, 200127, China
No. 160, Pujian Rd, Shanghai, 200127, China
No.160 Pujian Rd, Shanghai, 200127, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Neoadjuvant Apatinib Added to Weekly Paclitaxel and Cisplatin in Patient With Locally Advanced or Early Stage HER2 Negative Breast Cancer (APP) : a Open-label, Randomized, Controlled, Trial
Neoadjuvant Apatinib Added to Weekly Paclitaxel and Cisplatin in Patient With Locally Advanced or Early Stage HER2 Negative Breast Cancer (APP) : a Open-label, Randomized, Controlled, Trial
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2024
Intervention Type: Drug, Procedure
Study Drugs: Apatinib, Paclitaxel, Cisplatin
Study Phase: Phase 2
A Prospective, Randomized, Open-label Comparison of Preoperative Weekly Paclitaxel and Cisplatin With or Without Endocrine Therapy in Patients With Operable Hormone Receptor Positive and Triple Negative Locally Advanced Breast Cancer
A Prospective, Randomized, Open-label Comparison of Preoperative Weekly Paclitaxel and Cisplatin With or Without Endocrine Therapy in Patients With Operable Hormone Receptor Positive and Triple Negative Locally Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2023
Intervention Type: Drug
Study Drugs: Paclitaxel, Cisplatin, Gonadotropin-releasing hormone agonist, Letrozole
Study Phase: Phase 2/Phase 3
View 1 Less Clinical Trial

86 Total Publications

Asparagine endopeptidase prompts breast cancer-related pericardial calcification by regulating IGF2 and integrin αvβ5.
Asparagine endopeptidase prompts breast cancer-related pericardial calcification by regulating IGF2 and integrin αvβ5.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: December 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Lu's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile